Addressing a major global issue
The World Health Organization estimates that one in six people worldwide faces infertility issues. The scale of this problem highlights how urgent the need is for affordable and high-quality solutions. Conception can take several months even if there are no infertility problems, leading people to seek anything that could simplify the process, from ovulation tests to blood tests and more. But what if hormonal changes could be continuously monitored? This is exactly the problem Muun Health is aiming to solve with its innovative approach.
Muun Health was founded in 2023. The company’s founder, Kerli Luks, has a medical background with over a decade of experience working in various hospitals and clinics both in Estonia and abroad. “During clinical work, the need for continuous monitoring of female hormones became increasingly apparent, as current methods of analysis do not adequately reflect hormonal balance”, she explained. Of particular importance is that the fluctuations of female sex hormones require constant monitoring throughout the menstrual cycle, which cannot be done using current methods.
Synergy between innovation and scientific research
There are hundreds of methods and devices on the market for determining ovulation, but Muun Health is working to create a biosensor that is the simplest, fastest and most accurate of them. Muun Health’s device continuously measures female sex hormone levels, providing more information than other ovulation monitoring devices. Innovation and scientific research are integral parts of the company. “Only in this way can we create new personalised solutions that are also clinically significant”, said Luks.
The method that Muun Health uses to determine female sex hormones was created over ten years ago, but it has been extensively modified for use in their biosensor. The innovative process leverages new knowledge, earlier experience, and the scientific literature to create a completely new device that has great potential for the long term. In the future they plan to measure the levels of multiple hormones simultaneously, leading to even greater breakthroughs in health technology.
Promising early results
The response to Muun Health’s product has been very positive. There is a lot of interest in the device, especially among the target group of women aged 28-40. Luks stated that the next steps include further product development and creation of a prototype, followed by clinical trials and production work. The goal is to launch the device in the US market first, and then expand to the UK and European markets.
Although Muun Health only began laboratory testing in January this year, they have achieved a lot in a short time. A significant accomplishment is that they have proved that their method can determine the concentration of female sex hormones in interstitial fluid, which is about one hundredth of the level in serum.
Expectations for joining Tehnopol’s HealthTech Community
Muun Health founder Kerli Luks sees Tehnopol’s health technology community as a crucial support system for bringing the product to market. As the largest health-related ecosystem in the Baltics, Tehnopol offers the chance to learn from the experience of network members and to find partners to work with. Members can also participate in information events and receive mentor support in developing and implementing their strategy. The goal for Muun Health is to move into foreign markets, where they see that Tehnopol can provide significant support.
We are pleased to welcome Muun Health to Tehnopol’s health technology community and we look forward to seeing how their innovative solution simplifies the lives of families around the world!
